LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral
vascular devices and implants, today reported Q2 2011 financial
results. The Company posted record quarterly sales of $15.1mm, an
operating profit of $0.9mm and an adjusted operating profit of
$1.9mm. The Company also announced its exit from the stent graft
business, and the relocation of its California factory. Separately,
the Company declared a dividend of $0.02 per share, and provided Q3
2011 and full-year 2011 guidance.
Q2 2011 sales increased 7% versus Q2 2010. Sales in the Americas
grew 6%, while international sales increased 8%. By category,
Vascular grew 12% while Endovascular decreased 7%. Excluding stent
grafts, the effects of a weaker U.S. dollar and acquired LifeSpan
sales, organic sales growth in Q2 2011 was 3%.
The Company reported a gross margin of 68.6% in Q2 2011, versus
75.3% in Q2 2010. The decrease was largely due to the relocation of
its Italian factory to Burlington, manufacturing inefficiencies, as
well as the write-off of $0.4mm of stent graft inventory.
Excluding restructuring charges of $0.7mm, largely due to
distributor termination costs (Spain/Denmark), as well as the stent
graft inventory write-off, Q2 2011 operating income was $1.9mm.
Reported Q2 2011 operating income was $0.9mm, versus $2.0mm in the
year earlier period. Net income in Q2 2011 was $0.5mm or $0.03 per
diluted share, versus $1.5mm, or $0.09 per diluted share, in Q2
2010.
Cash and marketable securities as of June 30, 2011 were $21.4mm,
an increase of $2.3mm from $19.1mm at March 31, 2011. This increase
included the effects of dividends of $0.3mm and share repurchases
of $0.1mm during the quarter.
George W. LeMaitre, Chairman and CEO said, "The recent sale of
our TAArget/UniFit stent grafts and our exit from Endologix
European distribution will enable us to focus on our growing
vascular business. During the quarter we also announced the closure
of our California factory, which will consolidate all production
into Burlington. Meanwhile, we generated $2.3mm in cash in Q2 while
posting $1.9mm in adjusted operating income and record sales of
$15.1mm. With a tighter focus on vascular and a single factory, we
hope to begin posting cleaner quarters and better growth rates
going forward."
Q2 2011 operating expenses were $9.5mm. Excluding distributor
termination costs (Spain/Denmark), operating expenses in Q2 2011
were $8.8mm, up 3% from Q2 2010, as decreased R&D expenses and
general cost control largely offset increased G&A costs and the
effects of a weaker U.S. dollar.
Sales and marketing expenses increased 4% in Q2 2011 to $4.9mm.
The Company ended Q2 2011 with 65 sales representatives, up from 61
at the end of Q2 2010.
General and administrative expenses increased 15% in Q2 2011 to
$2.9mm. Increases were largely due to additional sales managers in
Spain and France, a weaker U.S. dollar and amortization of
intangible assets related to the LifeSpan acquisition.
R&D expenses decreased 22% to $1.0mm in Q2 2011, largely
driven by a reduction in regulatory and clinical affairs costs, as
stent graft clinical trial costs abated. The Company received
its CE mark for The UnBalloon in Q2 2011.
Quarterly Dividend
The Company's Board of Directors approved the payment of a
quarterly cash dividend on the Company's common stock of $0.02 per
share, with payment to be made on September 6, 2011 to shareholders
of record at the close of business on August 19, 2011. Future
declarations of quarterly dividends and the establishment of future
record and payment dates are subject to the final determination of
the Company's Board of Directors.
Business Outlook
The Company expects Q3 2011 sales of $14.6mm (+7% versus Q3
2010), and reported operating income of $1.5mm. The Company also
expects 2011 sales of $58.7mm (+5% versus 2010), and reported
operating income of $4.0mm.
The Company is reducing its full-year 2011 sales guidance by
$2.3mm due in large part to its exit from stent grafts.
Full-year operating income guidance is after approximately
$2.0mm of charges and special items associated with the five
strategic initiatives detailed below.
Five 2011 Initiatives – Focus on Vascular, Consolidate
Production & Expand Footprint
1) Endologix Early Termination - On July 18,
2011, the Company announced the early termination of its Endologix
stent graft distribution rights in Europe. Under the terms of the
agreement, Endologix will pay LeMaitre $1.3 million, and begin
selling direct on September 1, 2011.
2) Exit and Sale of TAArget/UniFit - On May 20,
2011, the Company announced that it would discontinue the
manufacture and sale of its TAArget/UniFit stent grafts. On June
30, 2011, the Company divested these product lines to Duke
Vascular.
3) Transfer of California Manufacturing - On
May 20, 2011, the Company announced the closure of its California
LifeSpan factory and the transfer of production to Burlington. Upon
completion, the Company will have centralized all of its production
activities into a single location. The transition is expected to be
largely complete in 2012.
4) Direct in Spain and Denmark - On July
1, 2011, the Company began selling its devices directly to Spanish
and Danish hospitals. The Company previously sold devices in Spain
and Denmark through independent distributors, and in 2010 sold
$0.7mm to these two customers.
5) Transfer of Italian Manufacturing - On
December 31, 2010, the Company closed its Italian factory and began
the transfer of production to Burlington. The transition is
expected to be largely complete in 2011.
Conference Call Reminder
Management will conduct a conference call at 5:00 p.m. EDT today
to review the Company's financial results and discuss its business
outlook for the remainder of the year. The conference call
will be broadcast live over the Internet. Individuals who are
interested in listening to the webcast should log on to the
Company's website at www.lemaitre.com/investor. The conference call
may also be accessed by dialing 800-322-2803 (+1-617-614-4925 for
international callers), using passcode 51869638. For individuals
unable to join the live conference call, a replay will be available
on the Company's website.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of
peripheral vascular disease, a condition that affects more than 20
million people worldwide. The Company develops, manufactures
and markets disposable and implantable vascular devices to address
the needs of its core customer, the vascular surgeon.
Well-known to vascular surgeons, the Company's diversified
product portfolio consists of brand name devices used in arteries
and veins outside of the heart, including the Expandable LeMaitre
Valvulotome and the Pruitt F3 Carotid Shunt.
LeMaitre and the LeMaitre Vascular logo are registered
trademarks of LeMaitre Vascular, Inc. This press release
contains other trademarks and trade names of the Company.
The LeMaitre Vascular, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10015
For more information about the Company, please visit
http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to properly
understand the Company's short-term and long-term financial trends,
investors may wish to consider the impact of certain non-cash or
non-recurring or infrequently-occurring items, when used as a
supplement to financial performance measures in accordance with
GAAP. These items result from facts and circumstances that
vary in frequency and/or impact on continuing operations. In
addition, management uses results of operations before such items
to evaluate the operational performance of the Company and as a
basis for strategic planning. Investors should consider these
non-GAAP measures in addition to, and not as a substitute for,
financial performance measures in accordance with GAAP. In
addition to the description provided below, reconciliation of GAAP
to non-GAAP results is provided in the financial statement tables
included in this press release.
In this press release, the Company has reported a non-GAAP
financial measure, adjusted operating income, which excludes
certain expenses related to the exit of our stent graft business
and the termination of our Spanish and Danish distributor
agreements. During Q2 2011, the Company incurred $0.4mm of
inventory write-offs related to its decision to discontinue its
TAArget and UniFit stent grafts product lines, which were charged
to cost of sales and are net of the Company's divestiture of these
product lines, $0.6mm of restructuring charges in connection with
transition payments to the Company's former distributors in Spain
and Denmark, which was charged to restructuring, and $0.1mm of
further costs related to the start-up of AlboGraft manufacturing in
Burlington, Massachusetts, which was charged to
restructuring. In Q2 2010, the Company incurred $0.1mm of
impairment charges in connection with its intangibles.
In addition, this press release includes sales growth after
adjusting for foreign exchange, business development transactions,
and other events. The Company refers to this as "organic" sales
growth. The Company analyzes net sales on a constant currency
basis net of acquisitions and other non-recurring events to better
measure the comparability of results between periods. Because
changes in foreign currency exchange rates have a non-operating
impact on net sales, and acquisitions, product discontinuations,
and other strategic transactions are episodic in nature and highly
variable in sales impact, the Company believes that evaluating
growth in sales on a constant currency basis net of such
transactions provides an additional and meaningful assessment of
sales to both management and the Company's investors. During Q2
2010, the Company divested the OptiLock Implantable Port and
discontinued sales of the aSpire Stent, and in Q4 2010, the Company
acquired its LifeSpan Vascular Graft business and discontinued its
Italian OEM manufacturing operations.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Statements in this press release regarding the Company's
business that are not historical facts may be "forward-looking
statements" that involve risks and
uncertainties. Specifically, statements regarding the
Company's financial and operational guidance, its future sales
growth, its plans to transition polyester graft manufacturing from
Brindisi, Italy to Burlington, Massachusetts, its plans to
transition LifeSpan graft manufacturing from California to
Burlington, Massachusetts and the termination of its distribution
of the Endologix stent graft, are forward-looking, involving risks
and uncertainties. The Company's current quarterly financial
results, as discussed in this release, are preliminary and
unaudited, and subject to adjustment. Forward-looking
statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties that could
cause actual results to differ from the results
predicted. These risks and uncertainties include, but are not
limited to, the risk that the Company is not successful in
transitioning to a direct selling model in Spain and Denmark; the
risk that the Company experiences production delays or quality
difficulties in the consolidation of its manufacturing operations;
the risk that the Company does not generate sufficient operating
scale to maintain or increase profitability; risks related to
product demand and market acceptance of the Company's products; the
possibility that the Company's new products may fail to provide the
desired safety and efficacy or may not be accepted by the market
for other reasons; the significant competition the Company faces
from other companies, technologies, and alternative medical
procedures; the risk that the Company may fail to expand its
product offerings through internal development or acquisition; the
general uncertainty related to seeking regulatory approvals for the
Company's products; and other risks and uncertainties included
under the heading "Risk Factors" in our most recent Annual Report
on Form 10-K, as updated by our subsequent filings with the SEC,
all of which are available on the Company's investor relations
website at http://www.lemaitre.com and on the SEC's website at
http://www.sec.gov. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they
are made. The Company undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events, or circumstances after the date they were made, or to
reflect the occurrence of unanticipated events.
Financial Statements
|
|
|
|
LEMAITRE VASCULAR, INC.
(NASDAQ: LMAT) |
|
|
CONDENSED CONSOLIDATED
BALANCE SHEETS |
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
June 30, 2011 |
December 31,
2010 |
|
|
(unaudited) |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ 21,405 |
$ 22,614 |
|
Accounts receivable, net |
9,066 |
8,475 |
|
Inventories |
7,811 |
8,375 |
|
Other current assets |
3,334 |
3,447 |
|
|
|
|
Total current assets |
41,616 |
42,911 |
|
|
|
|
Property and equipment, net |
4,027 |
3,806 |
Goodwill |
11,917 |
11,917 |
Other intangibles, net |
3,535 |
3,686 |
Deferred tax assets |
147 |
134 |
Other assets |
449 |
820 |
|
|
|
|
Total assets |
$ 61,691 |
$ 63,274 |
|
|
|
|
|
|
|
|
Liabilities and stockholders'
equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ 1,199 |
$ 1,320 |
|
Accrued expenses |
6,474 |
8,628 |
|
Acquisition-related
obligations |
689 |
441 |
Total current liabilities |
8,362 |
10,389 |
|
|
|
|
Deferred tax liabilities |
443 |
443 |
Other long-term liabilities |
82 |
86 |
|
Total liabilities |
8,887 |
10,918 |
|
|
|
|
Stockholders' equity |
|
|
|
Common stock |
162 |
161 |
|
Additional paid-in capital |
64,605 |
64,642 |
|
Accumulated deficit |
(8,000) |
(8,583) |
|
Accumulated other comprehensive
loss |
(6) |
(429) |
|
Less: treasury stock |
(3,957) |
(3,435) |
Total stockholders' equity |
52,804 |
52,356 |
|
|
|
|
Total liabilities and
stockholders' equity |
$ 61,691 |
$ 63,274 |
|
|
|
|
|
LEMAITRE VASCULAR, INC. (NASDAQ:
LMAT) |
|
|
|
|
CONDENSED CONSOLIDATED
STATEMENT OF OPERATIONS |
|
|
|
(amounts in thousands, except per share
amounts) |
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
For the six
months ended |
|
June 30, 2011 |
June 30, 2010 |
June 30, 2011 |
June 30, 2010 |
|
|
|
|
|
Net sales |
$ 15,112 |
$ 14,158 |
$ 29,710 |
$ 27,973 |
Cost of sales |
4,742 |
3,502 |
9,189 |
6,999 |
|
|
|
|
|
Gross profit |
10,370 |
10,656 |
20,521 |
20,974 |
|
|
|
|
|
Operating expenses: |
|
|
|
|
Sales and marketing |
4,916 |
4,747 |
9,889 |
9,641 |
General and administrative |
2,867 |
2,495 |
5,715 |
5,109 |
Research and development |
1,040 |
1,338 |
2,312 |
2,878 |
Restructuring charges |
650 |
-- |
1,655 |
-- |
Impairment charge |
-- |
68 |
83 |
68 |
|
|
|
|
|
Total operating expenses |
9,473 |
8,648 |
19,654 |
17,696 |
|
|
|
|
|
Income from operations |
897 |
2,008 |
867 |
3,278 |
|
|
|
|
|
Other income (loss): |
|
|
|
|
Interest income, net |
2 |
9 |
3 |
12 |
Other income, net |
5 |
(54) |
152 |
(28) |
|
|
|
|
|
Total other income (loss),
net |
7 |
(45) |
155 |
(16) |
|
|
|
|
|
Income before income taxes |
904 |
1,963 |
1,022 |
3,262 |
|
|
|
|
|
Provision for income taxes |
385 |
452 |
439 |
730 |
|
|
|
|
|
Net income |
$ 519 |
$ 1,511 |
$ 583 |
$ 2,532 |
|
|
|
|
|
Net income per share of common stock: |
|
|
|
|
Basic |
$ 0.03 |
$ 0.10 |
$ 0.04 |
$ 0.16 |
Diluted |
$ 0.03 |
$ 0.09 |
$ 0.04 |
$ 0.16 |
|
|
|
|
|
Weighted average shares outstanding: |
|
|
|
|
Basic |
15,470 |
15,613 |
15,468 |
15,646 |
Diluted |
16,071 |
16,050 |
16,064 |
16,045 |
|
|
|
|
|
|
|
|
|
|
Cash dividends declared per common
share |
$ 0.02 |
$ -- |
$ 0.04 |
$ -- |
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC.
(NASDAQ: LMAT) |
|
|
|
|
|
|
|
SELECTED NET SALES
INFORMATION |
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
For the six
months ended |
|
June 30,
2011 |
June 30,
2010 |
June 30,
2011 |
June 30,
2010 |
|
$ |
% |
$ |
% |
$ |
% |
$ |
% |
Net Sales by Product
Category: |
|
|
|
|
|
|
|
|
Vascular |
$ 11,436 |
76% |
$ 10,207 |
72% |
$ 22,196 |
75% |
$ 19,764 |
71% |
Endovascular |
2,725 |
18% |
2,944 |
21% |
5,626 |
19% |
6,236 |
22% |
Other |
951 |
6% |
1,007 |
7% |
1,888 |
6% |
1,973 |
7% |
Total Net Sales |
$ 15,112 |
100% |
$ 14,158 |
100% |
$ 29,710 |
100% |
$ 27,973 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales by
Geography |
|
|
|
|
|
|
|
|
Americas |
$ 9,415 |
62% |
$ 8,872 |
63% |
$ 18,417 |
62% |
$ 16,920 |
60% |
International |
5,697 |
38% |
5,286 |
37% |
11,293 |
38% |
11,053 |
40% |
Total Net Sales |
$ 15,112 |
100% |
$ 14,158 |
100% |
$ 29,710 |
100% |
$ 27,973 |
100% |
|
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC.
(NASDAQ: LMAT) |
|
|
|
|
|
|
|
|
|
IMPACT OF FOREIGN
CURRENCY AND BUSINESS ACTIVITIES |
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
2011 |
2010 |
2009 |
|
Q2 |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
|
|
|
|
|
|
|
|
|
|
|
Total net sales |
15,112 |
14,598 |
14,431 |
13,656 |
14,158 |
13,815 |
13,584 |
13,346 |
12,630 |
11,348 |
Impact of currency exchange rate fluctuations
(1) |
669 |
10 |
(420) |
(418) |
(336) |
314 |
613 |
(215) |
(699) |
(622) |
Net impact of acquisitions,
distributed sales and discontinued products, excluding
currency exchange rate fluctuations (2) |
259 |
283 |
56 |
(105) |
(65) |
95 |
397 |
333 |
234 |
101 |
|
|
|
|
|
|
|
|
|
|
|
(1) Represents the impact of the
change in foreign exchange rates compared to the corresponding
quarter of the prior year based on the weighted average exchange
rate for each quarter. |
(2) Represents the impact of
sales of products of acquired businesses and distributed sales of
other manufacturers' products, net of sales related to discontinued
and divested products, based on 12 months' sales following the date
of the event or transaction, for the current period only. |
|
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC.
(NASDAQ: LMAT) |
|
|
|
NON-GAAP FINANCIAL
MEASURES |
|
|
|
(amounts in thousands) |
|
|
|
(unaudited) |
|
|
|
|
|
|
|
Reconciliation between GAAP and
Non-GAAP organic sales growth excluding stent grafts: |
|
|
|
For the three months ended June
30, 2011 |
|
|
|
|
Net sales as reported |
$ 15,112 |
|
|
|
Impact of currency exchange
rate fluctuations |
(669) |
|
|
|
Net impact of stent graft
sales |
362 |
|
|
|
Net impact of acquisitions, distributed
sales and discontinued products, excluding currency |
(259) |
|
|
|
Adjusted net sales |
|
$ 14,546 |
|
|
|
|
|
|
|
For the three months ended June
30, 2010 |
|
|
|
|
Net Sales as reported |
|
$ 14,158 |
|
|
|
|
|
|
|
Adjusted net sales
increase for the three months ended June 30, 2011 |
|
$ 388 |
3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
For the six
months ended |
|
June 30, 2011 |
June 30, 2010 |
June 30, 2011 |
June 30, 2010 |
Reconciliation between GAAP and Non-GAAP
income from operations: |
|
|
|
|
Income from operations as
reported |
$ 897 |
$ 2,008 |
$ 867 |
$ 3,278 |
Inventory write-off from
terminated product line |
361 |
-- |
361 |
-- |
Restructuring charges |
650 |
-- |
1,655 |
-- |
Impairment |
-- |
68 |
83 |
68 |
|
|
|
|
|
Adjusted income from
operations |
$ 1,908 |
$ 2,076 |
$ 2,966 |
$ 3,346 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
For the six
months ended |
|
June 30, 2011 |
June 30, 2010 |
June 30, 2011 |
June 30, 2010 |
Reconciliation between GAAP and Non-GAAP
operating expenses: |
|
|
|
|
Operating expenses as reported |
$ 9,473 |
$ 8,648 |
$ 19,654 |
$ 17,696 |
Restructuring charges |
(650) |
-- |
(1,655) |
-- |
Impairment |
-- |
(68) |
(83) |
(68) |
|
|
|
|
|
Adjusted operating expenses |
$ 8,823 |
$ 8,580 |
$ 17,916 |
$ 17,628 |
CONTACT: J.J. Pellegrino
Chief Financial Officer
LeMaitre Vascular Inc.
781.221.2266 x106
jpellegrino@lemaitre.com
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From May 2024 to Jun 2024
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Jun 2023 to Jun 2024